Overview

Inhaled Ibuprofen to Treat COVID-19

Status:
Recruiting
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
The study aims to evaluate the reduction in severity and progression of lung injury with inhaled ibuprofen in patients with severe acute respiratory syndrome due to SARS-CoV-2 virus.
Phase:
N/A
Details
Lead Sponsor:
Química Luar SRL
Collaborators:
Centro de Excelencia en Productos y Procesos Córdoba
National Council of Scientific and Technical Research, Argentina
Treatments:
Ibuprofen